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Abstract
Mycolic acids (MA) are major, species-specific lipid components of Mycobacteria and
related genera. In Mycobacterium tuberculosis, it is made up of alpha-, methoxy- and keto-
MA, each with specific biological functions and conformational characteristics. Antibodies in
tuberculosis (TB) patient sera respond differently towards the three MA classes and were
reported to cross-react with cholesterol. To understand the antigenicity and cholesterol
cross-reactivity of MA, we generated three different chicken -derived phage-displayed sin-
gle-chain variable fragments (scFv) that reacted similarly towards the natural mixture of MA,
but the first recognized all three classes of chemically synthetic MAs, the second only the
two oxygenated types of MAs and the third only methoxy MA. The cholesterol cross-reactiv-
ity was investigated after grafting each of the three scFv types onto two configurations of
constant chain domains–CH1-4 and CH2-4. Weak but significant cross-reactivity with cho-
lesterol was found only with CH2-4 versions, notably those two that were also able to recog-
nize the trans-keto MA. The cholesteroid nature of mycobacterial mycolic acids therefore
seems to be determined by the trans-keto MA subclass. The significantly weaker binding to
cholesterol in comparison to MA confirms the potential TB diagnostic application of these
antibodies.
Introduction
Tuberculosis (TB) is an infectious disease that is caused by the Mycobacterium tuberculosis spe-
cies of bacteria [1]. Despite this being discovered already for over 100 years the disease contin-
ues to cause epidemics worldwide. TB is the leading cause of death due to infectious disease
globally, ranking higher than HIV/AIDS according to the latest World Health Organisation
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report of 2017 [2]. It maintains a heavy burden on economies and human health, not only in
the developing countries but also throughout the world. The latest statistics released by WHO
in 2017 reported that approximately 1.1 million people were living with TB and HIV co-infec-
tion worldwide. The diagnosis of TB is a challenging aspect impacting on the management of
the disease. Current TB diagnostic tests have been shown to still exhibit problems including:
long time period between testing and accurate diagnosis, not enough sensitivity, not always
accurate, and, in some cases, expensive. The 2017 WHO report stated that the diagnostic pipe-
line is progressing fast enough [2]. TB is a growing epidemic and will expand if the disease is
not curbed as soon as possible.
The mycobacterial cell envelope is made up of a variety of antigens of which mycolic acids
(MA) represent the major lipid component [3]. They occur either as free acids, linked to glyco-
lipids such as trehalose dimycolate or bound to arabinogalactan of the peptidoglycan layer [4–
6]. It is known that TB patients produce anti-mycolic acid antibodies (AMAA). The AMAA
levels are maintained in sera of HIV-infected TB patients regardless of a declining CD4+ T cell
count [7, 8]. This enables a biomarker test based on detection of AMAA to detect active TB
disease regardless of the HIV status of the patient, which is often the challenge with antibody
(Ab) biomarker tests. Although AMAA are known to exist in TB patients, the antigen moiety
of MAs that is recognized by the Abs is not known and the molecular basis that governs MA-
specific Ab-MA interactions is not well understood. A well-studied case of lipid antigen recog-
nition by Abs is that of cholesterol, where it has been demonstrated that Ab-lipid interactions
do not follow the classical Ab recognition mechanism defined for general proteins. A specific
protein antigenic epitope binds to a single Ab specificity, similar to enzyme-substrate recogni-
tion, but monoclonal Abs (mAbs) generated against cholesterol recognize the structural
arrangement of several cholesterol molecular moieties, rather than a single defined epitope.
Monoclonal Abs against cholesterol do not recognize it as a monomeric ligand or hapten, but
in its crystalline form, or when in monolayers [9, 10]. Interestingly, a mAb that recognizes cho-
lesterol with the hydroxyl functional group in the 3β-position cannot recognize epicholesterol
where the hydroxyl group is in the 3α-position, suggesting different packing of cholesterol
molecules in monolayers under different molecular arrangements. Moreover, the same mAb
cannot recognize ergosterol that has the same stereochemistry of the hydroxyl functional
group as cholesterol [11, 12]. This suggests that the specificity and/or selectivity of these struc-
ture-recognizing mAbs depend more on overall structural arrangement of particular steroid
molecules than on the specific antibody contact with a spatial orientation of single functional
groups of the steroid.
Unlike immobilized cholesterol, which forms from a homogeneous structure, naturally
occurring MAs (Fig 1) exist as a chemically heterogeneous mixture of three major classes
(alpha-, keto- and methoxy-MA).
These classes are characterized by the presence of chemical functional groups, viz. proximal
and distal cis-/trans-cyclopropane rings for alpha-MA, proximal cis-/trans-cyclopropane and
distal keto for keto-MA and proximal cis-/trans-cyclopropane and distal methoxy for meth-
oxy-MA [5, 6, 13, 14].
The chemical variations in MA molecule compositions are also present in the cell wall of M.
tuberculosis and differ remarkably between mycobacterial species [5, 6, 13]. Conformational
studies of MAs in Langmuir monolayers have shown that the three major classes adopt a four-
chain folded conformation that can be seen as a W-shape in two dimensions, with the mole-
cules folding at their proximal and distal functional groups. While keto-MA favored a rigid,
fully folded W-shape conformation, alpha- and methoxy-MA had partially folded conforma-
tions [15–17]. It was also shown that the folding and packing of MAs are influenced by the
classes, with oxygenated MAs containing α-methyl trans-cyclopropane groups folding more
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readily than those with cis-cyclopropane rings [18]. This suggests that depending on constitu-
ents of natural MAs mixture, the MA antigen will fold differently. The structural relatedness of
cholesterol and MAs is supported by (i) the fact that Amphotericin B binds to both MAs and
cholesterol, (ii) patient serum Abs produced against MAs cross-react with cholesterol, and (iii)
a single mAb against MA was found that binds both cholesterol and MAs [19, 20]. Notably, a
mAb against MA was also found that did not cross-react with cholesterol. The structural relat-
edness between cholesterol and MAs was reportedly responsible for the low accuracy in the
serodiagnosis of TB aimed at detecting AMAA using the ELISA assay [8]. It is well established
that all humans have anti-cholesterol antibodies (ACHA) in their blood [21], which may in
part explain the low Ab activity to MAs in TB negative patients. When designing an AMAA
biomarker based test it will be necessary to avoid the detection of cholesterol-binding cross-
reactive Abs.
Previously, researchers successfully generated MA-specific mAbs using phage display tech-
nology [19, 22]. The rationale for using phage display technology to generate MA-specific
mAb is that Abs can be generated against any antigen target, including non-immunogenic or
poorly immunogenic antigens such as lipids without the need for immunization [23, 24].
However, in order for mAbs to be used as research tools in diagnostics and in therapeutics,
they need to meet certain criteria: (i) be able to bind with adequate affinity and specificity to
the target, (ii) be stable and (iii) be readily produced in an affordable expression system such as
E. coli [25]. Although single chain variable Ab fragments (scFv) remain the most used mAb
formats [26, 27], they have stability and aggregation problems [28]. A number of different
strategies are used to increase scFv stability including Ab engineering after bio-panning/selec-
tion and stress-guided selection, i.e. selective pressures such as high temperatures, low pH or
high concentrations of guanidinium chloride [25, 29].
The current study was designed to investigate whether the antigenicity and cholesteroid
nature of MA is dependent on a particular MA subclass type rather than a combination
thereof. To confirm the cholesteroid nature of MAs and to determine the nature of its observed
cross-reactivity, a scFv chicken antibody gene library was screened for specific binders to MA
and cross-reactivity with cholesterol [30]. The rationale for using chicken antibodies is that,
Fig 1. Structures of the three major MA classes from Mycobacterium tuberculosis, alpha-MA (1), methoxy-MA (2)
and keto-MA (3).
https://doi.org/10.1371/journal.pone.0200298.g001
Antigenicity and cholesteroid nature of mycolic acids
PLOS ONE | https://doi.org/10.1371/journal.pone.0200298 August 9, 2018 3 / 19
like humans, chickens express specialized MA-presenting CD1 proteins for lipid antigen pre-
sentation. It is well-known that lipid antigens can be presented to T cells using CD1 proteins
on antigen presenting cells as presenter molecules. Although the CD1 family of molecules was
discovered and described in the late 1970s, their function as lipid and glycolipid antigen pre-
senting proteins was only recognized in the early 1990’s, when Beckman et al. showed that
CD1 proteins present mycobacterial MA on human dendritic cells to CD4/CD8 double nega-
tive T cells, causing these to become activated [31]. Mice were found not to have the specific
CD1 member that presents MA, but chickens do [32].
Three monoclonal chicken scFv Ab fragments with three different specificities were
selected: one recognizing all three MA subclasses and cholesterol, another only keto- and
methoxy-MA subclasses and a third only the methoxy-MA subclass. In addition, these scFv
fragments were engineered into two types of bivalent IgY formats [33] which we refer to as gal-
libodies, one a theoretically flexible CH1-4 construct and the other a truncated and hypotheti-
cally more rigid CH2-4 type as shown in Fig 2.
Materials and methods
Screening of the library for MA binders
The naïve semi-synthetic chicken phage-displayed scFv (Nkuku1) library containing 2 x 109
phage particles [30] was obtained from ARC-Onderstepoort Veterinary Institute (South
Africa). The library contains scFv Ab fragments displayed on recombinant M13 bacteriophage.
The scFv Ab fragments were derived from combinatorial pairings of chicken variable heavy
chain (VH) and variable light chain (VL) immunoglobulin domains. VH and VL domains are
linked by an interpeptide segment consisting of the sequence (GGGGS)3 enabling a fold typical
of scFvs. This library was panned as previously described for AMAA [19].
Briefly, Nunc-Maxisorp ELISA plates (Thermo Scientific, USA) were coated with 50 μl of a
natural isolated mixture of MAs (Sigma-Aldrich, USA) dissolved in freshly distilled hexane to
a final concentration of 250 μg/ml. The coated plates were allowed to evaporate at room tem-
perature and then incubated overnight at 4˚C. Plates were washed three times with 300 μl per
Fig 2. Structures of two types of vectors used for antibody engineering. A: scFvIgY (CH1-4) and B: scFvIgY (CH2-4).
Figure adapted from Greunke et al. [33].
https://doi.org/10.1371/journal.pone.0200298.g002
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well of phosphate buffered saline (PBS) containing 0.1% Tween 20. Two blocking agents, 2%
Casein (Cas)/PBS pH 7 and 3% bovine serum albumin (BSA)/PBS pH 7 were used alternately
during four consecutive rounds of panning to reduce the possibility of enriching for blocking
agent-specific binders. Plate wells were blocked with 300 μl of a blocking agent and incubated
for 2 h. The Nkuku1 phage library was pre-incubated with the blocking buffer for 30 min at
room temperature and then added to the MA-coated wells and incubated for 2 h at room tem-
perature. Plate wells were then washed twenty times with 300 μl per well of PBS/ 0.1% Tween
20 to remove unbound phages. Stringency of washing was increased during subsequent rounds
of panning by increasing the number of washes from three to twenty and simultaneously
increasing the wait period between washed from 30 s to 1 min. To elute phages displaying Ab
fragments that bound to MA, 150 μl of 100 mM trimethylamine was added to each well and
the plate was allowed to shake at (150 rpm) for 10 min. Eluted phage were then neutralised
with 150 μl of 1 M Tris, pH 7.4 and used to infect exponentially growing cultures of E. coli TG1
cells (New England Biolabs Inc., UK). After overnight growth, the bacteria were collected by
centrifugation. Phage particles were rescued using M13KO7 helper phage (New England Bio-
labs Inc., UK), precipitated with PEG/NaCl (20% polyethylene glycol 6000, 2.5 M NaCl) and
used as input for the next round of panning. Biopanning was sequentially repeated four times.
Phage-ELISA
Polyclonal populations of fusion phage produced after each round of selection were tested by
ELISA to confirm enrichment of MA-specific phage binders. To identify MA-specific mono-
clonal phage binders, individual bacterial clones were selected from each round of panning.
The MA-specific monoclonal phage binders were further assessed for their long-term storage
(four weeks) ability under different temperatures, cross-reactivity with cholesterol and non-
specific binding to hydrophobic ligands using the BSA system (previously described; [34]).
Nunc-Maxisorp ELISA plates were coated with 50 μl of natural mixture of MAs dissolved in
freshly distilled hexane to a final concentration of 250 μg/ml (for polyclonal phage) or 62.5 μg/
ml (for monoclonal phage). Cholesterol (Sigma-Aldrich, USA) was dissolved in hexane and
coated at both 0.250 mg/ml and 1 mg/ml. Bovine serum albumin was coated at 1 mg/ml. The
MA and cholesterol coated plates were allowed to have the hexane evaporate from them at
room temperature and were then incubated overnight at 4˚C. The following day, plates were
washed three times with 300 μl per well of PBS/0.1% Tween 20. The non-specific binding sites
were blocked with 300 μl per well of 2% Cas/PBS pH 7 for 2 h whereafter the plates were
washed three times with PBS/ 0.1% Tween 20. The PEG precipitated phages were mixed with
2% Cas/PBS-0.2% Tween 20 (1:1, v/v) and 50 μl of this mixture (test solution) was added to
each well and incubated for 1 h at 37˚C. The test solution was discarded and plates washed
three times with 300 μl per well of PBS/ 0.1% Tween 20. A mouse monoclonal anti-M13 mAb
B62-FE2 (PROGEN Biotechnik, Germany) was diluted 1:1000 in 2% Cas-PBS/0.1% Tween 20,
added to the wells (50 μl per well) and incubated at 30˚C for 60 min. The Ab solution was dis-
carded and the plates washed three times with 300 μl of PBS/0.1% Tween 20 per well to remove
the unbound Abs. Rabbit anti-mouse IgG conjugated to horseradish peroxidase (HRP) (Sigma
Aldrich, USA) was diluted 1:1000 in 2% Cas-PBS/0.1%Tween 20, was then added to each well
and incubated at 30˚C for 60 min. The Ab solution was discarded and the plate was washed
three times with 300 μl PBS/0.1% Tween 20 per well. The signal was developed by adding 50 μl
TMB Single Solution Chromogen for ELISA (Invitrogen™, Thermo Scientific, USA) to each
well and then incubated at room temperature for 30 min. To stop the reaction, 50 μl of 2 N
H2SO4 was added to each well. Plates were read using a Multiskan Ascent plate reader
Antigenicity and cholesteroid nature of mycolic acids
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(Thermo Scientific, USA) set at a measurement of 450 nm and a reference of 620 nm
wavelengths.
Characterization of mAbs binding activities against chemically synthetic
MAs
Synthetic, stereo-controlled single MAs were used to test the binding affinity of the phage
clones towards the different classes of MAs. The details on their synthesis have been reported
[35–42]. The ELISA plates were coated with the different synthetic MAs, namely a 50/50 (v/v)
mixture of synthetic MA (alpha- and methoxy-MA or alpha-and keto-MA). Natural MAs
served as antigen positive control. The lipids were dissolved in hexane to a final concentration
of 62.5 μg/ml and carrier hexane only coated wells served as antigen negative controls. After
coating, hexane was allowed to evaporate at room temperature and plates were incubated over-
night at 4˚C. Phage mAb clones of the same concentration (103 CFU per mL determined by
phagemid titre) were tested, using ELISA as described above.
DNA sequencing
To assess the uniqueness of individual phage clones, the nucleic acids were sequenced on an
Applied Biosystems ABI PRISM1 3100 Genetic Analyser (Foster City, USA) using the Big-
Dye1 Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, USA), which
is based on the dideoxy chain-termination DNA sequencing method of Sanger et al., 1997
[43]. Sequence alignment was carried out using BioEdit [44].The following primers were used
for amplification of scFv gene inserts from recombinant pHEN1 phagemid vector; forward
OP52 primer: 5’ CCCTCATAGGTTAGCGTAACG 3’ and reverse M13rev primer: 5’ CAG
GAAACAGCTATGAC 3’ (Inqaba Biotech, South Africa).
Evaluation of binding as single-chain fragments
Individual clones were grown overnight at 37˚C with shaking (220 rpm) in LB medium con-
taining 2% glucose and 100 μg/ml ampicillin. The following day, these cultures were inoculated
1:100 into 50 ml fresh medium containing glucose and ampicillin and grown to midlog
(OD600 = 0.9). The cultures were then centrifuged and the supernatant fluid (SNF) discarded.
Cell pellets were resuspended in 10 ml LB containing ampicillin and 1 mM isopropyl-β-D-
thiogalactoside (IPTG) and incubated overnight with shaking at 30˚C to induce expression of
soluble fragments. Secreted scFv fragments remain in the SNF and were isolated by centrifuga-
tion at 3000 rpm for 10 min at 4˚C. Cell pellets were retained to harvest periplasmic scFvs by
resuspending them in one-tenth volume of 1 × PBS supplemented with 1 M NaCl and 1 mM
EDTA and incubating on ice for 30 min. The fractions were centrifuged at 6000 × g for 10 min
at 4˚C and the SNFs containing the scFvs were transferred to fresh tubes. ELISA with MA was
conducted to confirm the functionality of the scFvs. Briefly, Nunc-Maxisorp ELISA plates
were coated with 50 μl of natural mixture of MAs (Sigma-Aldrich, USA) dissolved in freshly
distilled hexane to a final concentration of 250 μg/ml. The coated plates were allowed to have
the hexane evaporate from them at room temperature and were then stored until further use.
The following day, the ELISA plates were washed three times with 300 μl per well of PBS/0.1%
Tween 20. Non-specific binding sites were blocked with 300 μl per well of 4% milk powder/
PBS 1 hr at 37˚C and then washed three times with PBS/ 0.1% Tween 20. Isolated scFvs were
diluted with 2% milk powder/PBS-0.05% Tween 20 (1:1, v/v) and 50 μl of this mixture was
added to each well. Plates were incubated for 1 h at 37˚C. The test solution was discarded and
plates washed three times with 300 μl per well of PBS/ 0.1% Tween 20. Mouse anti-c-myc tag
mAb 9E10 (Onderstepoort, South Africa) diluted 1:1 in 4% milk powder-PBS/0.1% Tween 20
Antigenicity and cholesteroid nature of mycolic acids
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was added to the wells (50 μl per well) and the plates incubated at 37˚C for 1 h. The Ab solution
was discarded and the plates washed three times with 300 μl of PBS/0.1% Tween 20 per well to
remove any unbound Abs. Polyclonal rabbit anti-mouse immunoglobulin (Dako, Denmark)
diluted 1:1000 in 2% milk powder/PBS-0.05% Tween20 was added to the wells (50 μl per well)
and the plates incubated at 37˚C for 1 h. The conjugate solution was discarded and the plates
washed three times with 300 μl of PBS/0.1% Tween 20 per well. The signal was developed by
adding 50 μl of TMB Single Solution Chromogen for ELISA (Invitrogen™, Thermo Scientific,
USA) to each well and then incubated at room temperature for 15 min. To stop the reaction,
50 μl of 2 N H2SO4 was added to each well. Plates were read at 450 nm (Thermo Electron Cor-
poration Multiskan EX plate reader).
Antibody engineering
Single chain variable fragments antibody inserts were prepared for cloning following methods
previously described [45]. Briefly, scFv inserts were amplified from plasmid templates by PCR
using primers to introduce a BsiW (5’ GATCCGTACGGCCGTGACGTTGGACG 3’) and an
AscI (5’ GATCGGCGCGCCACCTAGGACGGTCAGGG 3’) cleavage site (Inqaba Biotech,
South Africa). Restriction digests were performed on scFv inserts (Anti-MA 12, 16 and 18)
and IgY-format expression vectors (scFvIgY (CH1-4) and scFvIgY (CH2-4)) [33] prior to sub clon-
ing. Ligated plasmids were transformed into JM109 chemically competent E. coli (Promega,
Madison, USA) and amplified under ampicillin resistance. Five clones from each ligation was
picked for colony PCR using the forward primer (5’ TAATACGACTCACTATAGGG 3’)
and reverse primer (5’ AGGAGGAGGGGTGGAGGACC 3’) to check for the presence
of the scFv inserts. Sequences obtained from analysis (Inqaba Biotech, South Africa) of plasmid
DNA were compared to the original templates using BioEdit [44].
Gallibody production and purification
Human embryonic kidney (HEK) 293-H cells (Invitrogen™, Carlsbad, USA) were grown to a
confluency of 80–100% in Dulbecco’s Modified Eagle Medium (DMEM)(ThermoFischer Sci-
entific, USA), supplemented with 10% (v/v) foetal bovine serum (FBS) and transfected with
2.5 μg plasmid DNA using TransIT1-293 Transfection Reagent (Mirus Bio Products,
Madison, USA). Cultures were grown at 37˚C and 5% CO2 gas. Successfully transfected cells
continued to grow under antibiotic selection (Zeocin ™, Invitrogen™, Carlsbad, USA) and were
expanded in fresh tissue culture flasks containing DMEM, 10% FBS and> 50 μg/ml Zeocin.
Gallibodies were purified from cell culture supernatants using nickel-nitrilotriacetic acid aga-
rose according to the manufacturer’s (QIAGEN1, Hilden, Germany) instructions. Purity and
specificity of the purified gallibodies was checked using SDS-PAGE (See S2 Fig), western blot
and ELISA. Purified gallibodies were concentrated in spin columns with a concurrent buffer
change (0.1 M borate buffer, pH 7.4) using Vivaspin 10 000 MW PES centrifugation columns
(VivaScience, Satorius Group, United Kingdom).
Gallibody ELISA
Nunc-Maxisorp ELISA plates were coated with 50 μl of natural mixture of MAs (Sigma-
Aldrich, USA) dissolved in freshly distilled hexane to a final concentration of 250 μg/ml. Cho-
lesterol was dissolved in hexane and coated at 1 mg/ml. The coated plates were allowed to have
the hexane evaporate from them at room temperature and were then stored until further use.
The following day, the ELISA plates were washed three times with 300 μl per well of PBS/0.1%
Tween 20. Non-specific binding sites were blocked with 300 μl per well of 2% Cas/PBS pH 7
for 2 hrs at 37˚C and then washed three times with PBS/ 0.1% Tween 20. Purified gallibodies
Antigenicity and cholesteroid nature of mycolic acids
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were diluted to 1 mg/ml with 2% Cas/PBS-0.2% Tween 20 (1:1, v/v) and 50 μl of this mixture
was added to each well. Two-fold serial dilutions of each gallibody were prepared on the antigen
coated plates, with the concentration range varying from 2 μg/ml to 1000 μg/ml. Plates were
incubated for 1 h at 37˚C. The test solution was discarded and plates washed three times with
300 μl per well of PBS/ 0.1% Tween 20. Goat anti-chicken Fc: HRP (AbD Serotec, Kidlington,
UK) diluted 1:1000 in 2% Cas-PBS/0.1% Tween 20 was added to the wells (50 μl per well) and
the plates incubated at 30˚C for 1 h. The Ab solution was discarded and the plates washed three
times with 300 μl of PBS/0.1% Tween 20 per well to remove any unbound Abs. The signal was
developed by adding 50 μl of TMB Single Solution Chromogen for ELISA (Invitrogen™, Thermo
Scientific, USA) to each well and then incubated at room temperature for 5 min on MA and 20
min on cholesterol, respectively. To stop the reaction, 50 μl of 2 N H2SO4 was added to each
well. Plates were read at 450 nm (Thermo Electron Corporation Multiskan EX plate reader).
Statistical analyses
In order to normalize antibody binding signals between different plates, the ratio differences
of antibody binding signals relative to casein blocked non-antigen coated wells was deter-
mined and data adjusted accordingly. Data analyses was performed using the student’s t-test at
a confidence level of 95%.
Results
Affinity enrichment of chicken antigen specific phage binders by bio-
panning
To evaluate fusion phage specificity, individual clones were selected from the pooled outputs
of all four rounds of panning. Only phage binders that retained reactivity to MA after 1 week
of storage at 4˚C were used as a pool for selecting stably expressed monoclonal phage binders
[25]. The next step was to distinguish true binders from false binders in the stable pool of
phage binders. Approximately 270 individual clones were screened by phage-ELISA assay.
Although a large number of unspecific phages remained after numerous panning rounds,
these were reduced to five which were shown to be stable after one week of incubation at 4˚C
[46]. Two bound specifically to MA, another reacted with both MA and cholesterol and the
remaining bound non-specifically.
Cholesterol and MA cross-reactive phage-displayed scFv mAb
The specificities of the three MA reactive phage clones were further evaluated by ELISA. Dena-
tured BSA system was used with exposed hydrophobic patches that are hidden in native BSA
[34]. If the monoclonal phage-fused scFv Abs are not specific to MA, it is expected that they
would also bind to hydrophobic patches of BSA. Our results show that anti-MA 12 reacted
with both cholesterol (at the higher concentration of 1 mg/ml) and MAs. The binding to these
molecules is selective, as anti-MA 12 did not bind to either native BSA (NBSA) or denatured
BSA (DBSA) through hydrophobic interactions. Anti-MA 16 and anti-MA 18 showed slight
binding to cholesterol only at the higher concentration (p< 0.005) but were not reactive to
BSA (Fig 3).
MA-specific phage-displayed scFvs have different fine specificities of MA
binding
The fine specificities of the isolated mAbs to MAs were then investigated using stereo-con-
trolled chemically synthetic MA classes (alpha-, keto- and methoxy-) in ELISA (Fig 4).
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Anti-MA 12 recognized all classes of MAs. Anti-MA 16 reacted with all classes of MAs
except cis-keto. Anti-MA 18 bound strongly and exclusively to methoxy MA of either cis- or
trans- configuration and irrespective of whether associated with 50% alpha-MA composition.
Alpha-MA did not influence the antigenic properties of MA, since a combination of either
keto- or methoxy- with alpha-MA did not result in reduced or enhanced recognition of MA
antigen by the selected mAbs.
Amino acid sequences of the hypervariable regions of the MA-specific
phage-displayed scFvs
Since anti-MA 12, 16 and 18 were shown to bind with three unique specificities, the Abs were
sequenced to test whether their amino acid sequences are also different. The alignment
(Table 1) showed the expected homology between the three monoclonal scFv Abs for the
framework regions as reported in literature [30], while the complementarity-determining
regions (CDRs) differed.
It is known that the heavy chain CDR3 plays the dominant role in the observed binding
specificity of Abs. The specificity conferred by the heavy chain is preserved regardless of its
Fig 3. Evaluation of the selectivity and specificity of MA-reactive fusion-phage clones in ELISA. Natural MA was used as a positive control, while
denatured bovine serum albumin (DBSA), native bovine serum albumin (NBSA) and hexane were used as negative controls. MAs were coated at 0.250
mg/ml while cholesterol was coated at both 0.250 mg/ml and 1 mg/ml. The concentration of bovine serum albumin used was 1 mg/ml. Error
bars = Standard error of mean, n = 5 (biological repeats). See S1 Dataset.
https://doi.org/10.1371/journal.pone.0200298.g003
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pairing with various light chains [47]. The CDR1 and CDR2 regions of both heavy and light
chains showed minimal sequence diversity, but the CDR 3 regions of both heavy and light
chains confirmed that the three monoclonal scFv Abs are unique (Table 1). The most striking
result was that the anti-MA mAb 18 showed significantly longer CDR3 regions in both the
heavy and the light chain. Whereas CDR1 and CDR2 are known to come about by point muta-
tion only, the larger CD3 additionally comes about by rearrangement of the V genes with D
genes (H- chain) and J genes (H- and L- chains) with intermittent random nucleotide
insertions.
Mycolic acid specific monoclonal gallibodies
The clones produced during the antibody engineering process were sequenced to determine
the success of the subcloning procedure. Three of the newly generated clones for each of the
two gallibody constant chain frames (CH1-4 and CH2-4) were selected for the subsequent gal-
libody production (see S1 Fig).
To confirm the specificity of the monoclonal antibodies following the conversion from
phage-displayed scFvs to purified monoclonal IgY-like antibodies (See S2 Fig), gallibodies
were analysed with ELISA on MA. Samples were loaded at a starting concentration of 1000 μg/
ml of gallibody and titrated down to 2 μg/ml on the antigen coated plates.
Fig 5A shows that gallibody 12CH2-4 was able to bind MA across the entire concentration
range, with the amount of binding remaining the same even when an antibody concentration
as low as 2 μg/ml was used. The sensitivity for gallibody 12CH2-4 was reached when the anti-
body was used at a concentration of 1 μg/ml (Fig 5A1). The sensitivity for gallibody 12CH1-4 on
MA was weaker at A50% = 4 μg/ml. A50% was determined by identifying the concentration of
gallibody where absorbance was approximately 50% of the highest signal.
Gallibody 16 showed a slightly weaker sensitivity of MA binding at A50% of 25 μg/ml and
8 μg/ml for gallibody 16CH1-4 and 16CH2-4, respectively. Gallibody 18 showed the weakest bind-
ing to MA with A50% for gallibody18CH1-4 at 75 μg/ml and gallibody 18CH2-4 at 16 μg/ml.
Nature of cholesterol cross-reactivity
In an attempt to probe the cholesterol cross-reactivity of MA, the gallibodies’ ability to bind to
cholesterol was analysed with ELISA. Fig 6 illustrates the cholesterol cross-reactivity for all the
gallibodies.
Fig 4. Characterization of the binding specificities of MA-specific phage-displayed Abs with ELISA using single
stereo-isomers of stereo-controlled synthetic MAs, their 1:1 mixtures with α-MA and natural MA mixture. In this
monoclonal phage ELISA assay, the coating of MA antigens was done by adding 50 μl per well of MA (62.5 μg/ml)
dissolved in hexane. Hexane alone was used as a negative control. A) Anti-MA 12, B) Anti-MA 16, C) Anti-MA 18.
Error bars = Standard error of mean, n = 8 (biological repeats) t = trans, c = cis. The experiments on all synthetic MAs
were performed with the three mAbs in parallel under the same conditions. This result is a representative of more than
three biological repeats with six technical repeats for each mAb. See S1 Dataset.
https://doi.org/10.1371/journal.pone.0200298.g004
Table 1. Deduced amino acid sequences of CDR 3 regions for phage displayed monoclonal scFv Abs isolated against MA.
Clone VH CDR3 VL CDR3
Anti-MA mAb 12 MNYRRRQ TEDSTY
Anti-MA mAb 16 RRITNK RDSGAP
Anti-MA mAb 18 RKTNKHRIDAWGHGTEV GSYEASNSAGIFG
VH variable heavy chain, VL variable light chain
https://doi.org/10.1371/journal.pone.0200298.t001
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The results show that all of the CH1-4 gallibody types (12CH1-4, 16CH1-4 and 18CH1-4) and
one of the CH2-4 type (18CH2-4) did not produce signals that were significantly different from
the antigen negative control, indicating that these antibodies were not able to cross-react with
cholesterol. In contrast, the truncated gallibody 12CH2-4 and 16CH2-4 cross-reacted with choles-
terol. The binding signal of gallibody 16CH2-4 was more than two fold higher than the 12CH2-4
version, suggesting that the former has a higher affinity for cholesterol.
Fig 5. Gallibody binding to natural MAs in ELISA. Coating of MA antigens was done at 250 μg/ml in hexane.
Hexane alone was used as a negative antigen control for background correction of the data. A) Anti-MA 12, B) Anti-
MA 16, C) Anti-MA 18. Error bars = Standard deviation, n = 8 (biological repeats), CH1-4 = full length constant
region, CH2-4 = truncated constant region. This result is representative of two biological repeats with four technical
repeats for each concentration of gallibody. Insert A1) represents gallibody 12CH2-4 titration at lower concentrations.
No non-specific binding of gallibodies was observed when the antigen negative control was used. See S2 Dataset.
https://doi.org/10.1371/journal.pone.0200298.g005
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Fig 6. Cholesterol cross-reactivity of gallibodies confirmed with ELISA using hexane solvent alone as negative
control. Coating of cholesterol was done at 1 mg/ml in hexane. A) Anti-MA 12, B) Anti-MA 16, C) Anti-MA 18. Error
bars = Standard deviation, n = 8 (biological repeats) CH1-4 = full length constant region, CH2-4 = truncated constant
region. The results each represent two biological repeats with four technical repeats for each concentration of
gallibody. The data were extracted from the same experiment that was performed in Fig 5, making the absorbance
readings from both figures directly comparable. See S3 Dataset.
https://doi.org/10.1371/journal.pone.0200298.g006
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Discussion
Our group previously demonstrated that it is feasible to generate MA-specific recombinant
scFv antibody fragments from a semi-synthetic chicken antibody-gene library [19]. We used
the approach that Beukes et al., (2010) used previously to pan for MA-specific Abs from the
recombinant chicken antibody library, but selected for thermally stable scFvs. Similarly to
Beukes and colleagues (2010), both cholesterol cross-reactive and non-cross-reactive anti- MA
phage antibodies were isolated [19].
It appeared as if all the anti-MA phage antibodies recognised cholesterol, with anti-MA 12
giving the highest binding. The binding to cholesterol was much weaker than the binding to
MA. We confirmed the specificity of cholesterol binding by using denatured BSA as a negative
antigen control. The phage-displayed antibodies showed increased binding to a higher concen-
tration of cholesterol, confirming that cholesterol is more antigenic at the higher concentration
as reported by other authors [10].
While the method of phage display technology is useful for selecting scFvs with different
binding specificities, it has been reported that soluble scFvs have the ability to naturally form
dimers and trimers [48, 49], forming multivalent non-covalently bound antibody fragments.
This may give false-positive cross-reactive binding due to the uncontrolled valency for antigen
binding. While the soluble scFvs retained their ability to bind to MA, the data obtained
revealed their low binding affinity (data not shown). Thus in order to truly define the binding
specificities of the selected mAbs, the three scFvs were subcloned into bivalent IgY expression
vectors. Results of the gallibody characterization were in agreement with those obtained with
phage-displayed Abs, illustrating that all gallibodies bound to MA with approximately equal
strength. Cholesterol binding results revealed that only the CH2-4 gallibody subtypes of anti-
MA 12 and anti-MA 16 bound to cholesterol at high antibody concentrations. Furthermore, in
contrast to the results obtained with phage antibodies, where phage antibody 12 bound stron-
gest to cholesterol, gallibody 16CH2-4 now displayed the highest binding. This emphasizes the
importance of controlling both protein concentration and antigen binding valency for quanti-
tatively comparing cross-reactivity of anti-MA antibodies. Gallibody 18CH2-4 qualified the
result found with phage antibody 18 in that it showed no affinity of binding for cholesterol.
Methoxy MA is known to be the most antigenic for sensitive detection of anti-MA detection
in TB patients [19, 22]. Anti-MA 18, which recognizes methoxy-MA but not keto-MA, has a
very unique and long CDR3 region compared to anti-MA12 and anti-MA 16. The CDR3
region is the main carrier of diversity and specificity in the Ab binding site. Other researchers
have shown that not only are the differences in sequence of the CDR3 heavy chains between
Abs important in determining specificities but also the length of CDR3 heavy chains [50].
In a study by Chan and colleagues (2013) aimed at generating anti-MA Abs from a human
antibody gene library using phage-display technology, the authors reported that they could not
find a cholesterol cross-reactive anti-MA Ab [22]. This observation is corroborated by our
findings of all three CH1-4 gallibodies. However, cross-reactivity with cholesterol was
observed with gallibody 12CH2-4 and gallibody 16CH2-4 at high antibody concentrations
(1000 μg/ml and 500μg/ml). Gallibody 12 and 16 both have specificity for binding to trans-
keto MA as such or in combination with alpha- or methoxy- MAs. In the study of Chan et al.,
all anti-MA Ab generated could not recognize keto-MA but had weak binding to alpha-MA.
Our study corroborates this finding as the 18CH2-4 gallibody–which also does not recognize
keto MA–similarly did not cross-react with cholesterol. Anti-MA 18 only recognizes methoxy
mycolate as such or in combination with alpha-MA (Fig 4). Anti-MA 16 recognizes all the syn-
thetic MAs and combinations thereof, except cis-keto MA (Fig 4). Notably the lack of specific-
ity of anti-MA 16 towards binding of cis-keto MA had no influence on the cholesterol cross-
Antigenicity and cholesteroid nature of mycolic acids
PLOS ONE | https://doi.org/10.1371/journal.pone.0200298 August 9, 2018 14 / 19
reactivity. Due to these findings, it seems likely that the cholesteroid nature of the MA antigen
manifests in the fine specificity towards the trans-keto MA subtype.
Interestingly, an involvement of keto MA with cholesterol in vivo has recently been
reported by Vermeulen et al. [51]. These authors wanted to determine the effect that the differ-
ent MA subclasses have on the growth of the mycobacteria in macrophages, particularly the
accumulation of cholesterol brought about by the M. tuberculosis organism during disease pro-
gression. Their results revealed that the keto MA is responsible for the accumulation of intra-
cellular lipid droplets packed with cholesterol. Furthermore, when mouse macrophages were
treated with keto MA, bacterial growth was largely unrestricted compared to those treated
with alpha- or methoxy- MA.
Notably, from the results obtained it was only selective CH2-4 gallibody types that displayed
cholesterol cross-reactivity. None of the CH1-4 gallibodies possessed this ability. This finding
can be related to the structures of the two IgY framework constructs used for antibody engi-
neering. The IgY immunoglobulin class of antibodies has been described in the literature as
the avian population’s equivalent of the IgG subclass. While these antibodies are similar in
structure, one of the most notable differences is the IgY subclass’ lack of a hinge region [52].
These antibodies (IgY) rely on their CH1 and CH2 domains for flexibility, with the CH1
domain contributing largely in this respect [53]. As a result of this and the fact that the CH2-4
construct lacks the CH1 domain, one may refer to the two gallibody subtypes as the flexible
CH1-4 and the rigid truncated CH2-4. The CH2-4 versions of the three antibody specificities
were generally more sensitive for antigen binding than the CH1-4 versions. This may explain
why only the rigid CH2-4 anti-MA monoclonal antibodies cross-react to cholesterol. It is
probably due to divalent binding to repeating cholesteroid epitopes on clusters of immobilized
MA, which is enhanced by better positive cooperative binding of the two more closely cropped
Fab domains on CH2-4 antibody constructs. Mathebula et al. (2009) previously showed how
mycolic acids cluster into small islands on a self-assembled monolayer of octadecane thiol
[54]. The cholesteroid epitopes in the clusters may be too close, and the MA clusters too far
apart to be recognized divalently by the more flexible and larger CH1-4 type of gallibody. Thus
the binding of the two CH2-4 gallibodies is probably due to the enhanced co-cooperativity aid-
ing in the sensitivity.
The weak affinity of these recombinant mAbs relates to the binding activity of natural anti-
bodies to MA found in TB patient sera. Previously research conducted within our research
group demonstrated this property of AMAA–their low affinity. While these antibodies can be
detected using ELISA, we revealed how cases can be missed when this standard technique is
used for detection [8, 55]. As a result of this more sensitive biosensor techniques for detecting
these AMAA, are applied for the diagnosis of TB patients [7].
It has been shown before that the three MA major classes (alpha-, keto- and methoxy-
MA) of M. tuberculosis have varying antigenicity with respect to antibody recognition and
that cross-reactive antibodies binding to both MA and cholesterol exist in human sera. This
has now been investigated using recombinant anti-MA mAbs derived from a recombinant
chicken Ab repertoire. The major findings of this study substantiate the dominant antigenic
nature of methoxy-MA reported before, while now demonstrating that the cholesteroid
nature of MAs seems to depend on the ability of the AMAA to recognize the trans-keto MA
subtype.
Supporting information
S1 Fig. Sequences of gallibody clones produced by antibody engineering. 12) Anti-MA 12,
16) Anti-MA 16, 18) Anti-MA 18, CH1-4 = full length constant region, CH2-4 = truncated
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constant region, VH = variable heavy chain, VL = variable light chain.
(TIF)
S2 Fig. SDS-PAGE analysis illustrating gallibody purification using Ni-NTA affinity col-
umns. A) 12CH1-4, B) 16CH1-4, C) 18CH1-4, D) 12CH2-4, E) 16CH2-4, F) 18CH2-4. Gel lanes 1)
Marker, 2) Culture supernatant, 3) Flow through 1, 4) Flow through 2, 5) Washes, 6) Elution
1, 7) Elution 2, 8) Elution 3, 9) Elution 4. Successful purification is demonstrated by the com-
parable thickness of the 67 kDa band obtained with the culture supernatant (2) and the elu-
tions (6–9).
(TIF)
S1 Dataset. Experimental data used for producing Figs 3 and 4.
(XLSX)
S2 Dataset. Experimental data used for producing Fig 5.
(XLSX)
S3 Dataset. Experimental data used for producing Fig 6.
(XLSX)
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